AR085668A1 - Terapias combinadas para malignidades hematologicas - Google Patents
Terapias combinadas para malignidades hematologicasInfo
- Publication number
- AR085668A1 AR085668A1 ARP120100805A ARP120100805A AR085668A1 AR 085668 A1 AR085668 A1 AR 085668A1 AR P120100805 A ARP120100805 A AR P120100805A AR P120100805 A ARP120100805 A AR P120100805A AR 085668 A1 AR085668 A1 AR 085668A1
- Authority
- AR
- Argentina
- Prior art keywords
- hematological
- malignities
- combined therapies
- alkyl
- pharmaceutically acceptable
- Prior art date
Links
- 230000002489 hematologic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002707 bendamustine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229960002450 ofatumumab Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyesters Or Polycarbonates (AREA)
- Stored Programmes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452034P | 2011-03-11 | 2011-03-11 | |
| US201161493317P | 2011-06-03 | 2011-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085668A1 true AR085668A1 (es) | 2013-10-16 |
Family
ID=45888489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100805A AR085668A1 (es) | 2011-03-11 | 2012-03-12 | Terapias combinadas para malignidades hematologicas |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20130064812A1 (OSRAM) |
| EP (2) | EP2683377A1 (OSRAM) |
| JP (2) | JP2014510729A (OSRAM) |
| KR (1) | KR20140022836A (OSRAM) |
| CN (1) | CN103826629A (OSRAM) |
| AP (1) | AP2013007158A0 (OSRAM) |
| AR (1) | AR085668A1 (OSRAM) |
| AU (2) | AU2012229266A1 (OSRAM) |
| BR (1) | BR112013022801A2 (OSRAM) |
| CA (1) | CA2829096A1 (OSRAM) |
| CL (1) | CL2013002552A1 (OSRAM) |
| CO (1) | CO6821936A2 (OSRAM) |
| CR (1) | CR20130517A (OSRAM) |
| EA (1) | EA201391263A1 (OSRAM) |
| EC (1) | ECSP13012964A (OSRAM) |
| MA (1) | MA35090B1 (OSRAM) |
| MX (1) | MX2013010439A (OSRAM) |
| PE (1) | PE20140405A1 (OSRAM) |
| PH (1) | PH12013501855A1 (OSRAM) |
| SG (2) | SG193337A1 (OSRAM) |
| TW (1) | TW201242598A (OSRAM) |
| UY (1) | UY33947A (OSRAM) |
| WO (1) | WO2012125510A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP2010209B1 (en) | 2006-04-10 | 2016-06-15 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| ES2674719T3 (es) | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Terapias para neoplasias hematológicas |
| PE20180318A1 (es) | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| PL2945647T3 (pl) | 2013-01-15 | 2021-03-08 | Memorial Sloan Kettering Cancer Center | Immunogenne peptydy wt-1 i sposoby ich zastosowania |
| US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
| CN103271897A (zh) * | 2013-06-04 | 2013-09-04 | 李春启 | 美司那在制备抗血管生成类药物中的应用 |
| ES2535452B1 (es) * | 2013-08-02 | 2016-03-02 | Dalana3 S.L. | Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas |
| US20150148345A1 (en) * | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| DK3148532T3 (en) | 2014-05-28 | 2021-04-26 | Piramal Entpr Ltd | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer |
| MA40250A (fr) | 2014-07-04 | 2017-05-10 | Lupin Ltd | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k |
| CN105380956B (zh) * | 2015-11-04 | 2017-12-19 | 张陆军 | 一种治疗白血病的含艾德拉尼的药物组合物及应用 |
| UA125216C2 (uk) * | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| JP7355294B2 (ja) * | 2017-11-30 | 2023-10-03 | シンガポール ヘルス サービシズ ピーティーイー． リミテッド | がん患者を適切ながん処置群に分類するためのシステム及び方法、並びに患者を処置するための化合物 |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
| CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117889A1 (en) * | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic |
| ES2674719T3 (es) * | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Terapias para neoplasias hematológicas |
| MX2011011036A (es) * | 2009-04-20 | 2012-01-20 | Gilead Calistoga Llc | Metodos de tratamiento para tumores solidos. |
| EA201890869A3 (ru) * | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
-
2012
- 2012-03-09 EP EP12710838.9A patent/EP2683377A1/en not_active Withdrawn
- 2012-03-09 EA EA201391263A patent/EA201391263A1/ru unknown
- 2012-03-09 US US13/417,180 patent/US20130064812A1/en not_active Abandoned
- 2012-03-09 WO PCT/US2012/028654 patent/WO2012125510A1/en not_active Ceased
- 2012-03-09 KR KR1020137026766A patent/KR20140022836A/ko not_active Withdrawn
- 2012-03-09 BR BR112013022801A patent/BR112013022801A2/pt not_active IP Right Cessation
- 2012-03-09 CA CA2829096A patent/CA2829096A1/en not_active Abandoned
- 2012-03-09 SG SG2013067129A patent/SG193337A1/en unknown
- 2012-03-09 EP EP17157706.7A patent/EP3187184A1/en not_active Withdrawn
- 2012-03-09 PE PE2013002034A patent/PE20140405A1/es not_active Application Discontinuation
- 2012-03-09 JP JP2013557934A patent/JP2014510729A/ja active Pending
- 2012-03-09 AU AU2012229266A patent/AU2012229266A1/en not_active Abandoned
- 2012-03-09 SG SG10201601909TA patent/SG10201601909TA/en unknown
- 2012-03-09 MX MX2013010439A patent/MX2013010439A/es not_active Application Discontinuation
- 2012-03-09 AP AP2013007158A patent/AP2013007158A0/xx unknown
- 2012-03-09 CN CN201280022394.XA patent/CN103826629A/zh active Pending
- 2012-03-09 PH PH1/2013/501855A patent/PH12013501855A1/en unknown
- 2012-03-12 UY UY0001033947A patent/UY33947A/es not_active Application Discontinuation
- 2012-03-12 AR ARP120100805A patent/AR085668A1/es unknown
- 2012-03-12 TW TW101108394A patent/TW201242598A/zh unknown
-
2013
- 2013-09-05 CL CL2013002552A patent/CL2013002552A1/es unknown
- 2013-09-30 CO CO13231986A patent/CO6821936A2/es not_active Application Discontinuation
- 2013-10-03 MA MA36292A patent/MA35090B1/fr unknown
- 2013-10-08 CR CR20130517A patent/CR20130517A/es unknown
- 2013-10-10 EC ECSP13012964 patent/ECSP13012964A/es unknown
-
2015
- 2015-01-16 US US14/599,287 patent/US20150196564A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/199,666 patent/US20170119771A1/en not_active Abandoned
- 2016-07-27 JP JP2016147201A patent/JP2016222700A/ja active Pending
- 2016-09-16 AU AU2016228272A patent/AU2016228272A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2683377A1 (en) | 2014-01-15 |
| PH12013501855A1 (en) | 2018-03-21 |
| US20130064812A1 (en) | 2013-03-14 |
| JP2016222700A (ja) | 2016-12-28 |
| WO2012125510A1 (en) | 2012-09-20 |
| SG193337A1 (en) | 2013-10-30 |
| EA201391263A1 (ru) | 2014-06-30 |
| JP2014510729A (ja) | 2014-05-01 |
| PE20140405A1 (es) | 2014-03-22 |
| CO6821936A2 (es) | 2013-12-31 |
| MX2013010439A (es) | 2014-07-09 |
| BR112013022801A2 (pt) | 2019-09-24 |
| CR20130517A (es) | 2014-02-12 |
| CN103826629A (zh) | 2014-05-28 |
| US20170119771A1 (en) | 2017-05-04 |
| ECSP13012964A (es) | 2014-02-28 |
| TW201242598A (en) | 2012-11-01 |
| AU2016228272A1 (en) | 2016-10-06 |
| EP3187184A1 (en) | 2017-07-05 |
| AU2012229266A1 (en) | 2013-05-02 |
| MA35090B1 (fr) | 2014-05-02 |
| KR20140022836A (ko) | 2014-02-25 |
| AP2013007158A0 (en) | 2013-10-31 |
| CL2013002552A1 (es) | 2014-09-05 |
| UY33947A (es) | 2012-10-31 |
| SG10201601909TA (en) | 2016-04-28 |
| US20150196564A1 (en) | 2015-07-16 |
| CA2829096A1 (en) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085668A1 (es) | Terapias combinadas para malignidades hematologicas | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| MX2019002774A (es) | Inhibidores de la recirculacion de acidos biliares para el tratamiento de hipercolemia y enfermedad hepatica colestasica. | |
| PE20160194A1 (es) | Composiciones y metodos para tratar anemia | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| EA201690989A1 (ru) | Ингибиторы syk | |
| AR084469A1 (es) | Combinaciones de inhibidores de quinasas para el tratamiento del cancer | |
| BR112012023021A2 (pt) | compostos de indazol e seus usos | |
| MY185103A (en) | Bezylamine derivatives as inhibitors of plasma kallikrein | |
| HK1201065A1 (en) | Novel quinoxaline inhibitors of pi3k | |
| UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201490396A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| ECSP13012658A (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| ECSP14013239A (es) | Composiciones farmacéuticas | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| EA201390626A1 (ru) | Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| BR112014010729A2 (pt) | métodos para tratamento de ataques de gota |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |